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We investigated a series of 122 cases of small cell lung carcinomas and non-small cell lung carcinomas for the presence of several
viruses that are known to be oncogenic in humans. Thus, viral genomes (DNA) and/or RNA transcripts and/or proteins of human
papillomaviruses (HPV) 16, 18, 31, 33, 51, Epstein–Barr virus (EBV), human herpesvirus 8 (HHV-8), human cytomegalovirus (HCMV)
and simian virus 40 (SV40) were investigated on tissue sections (prepared in tissue microarrays) with different techniques of
immunohistochemistry and in situ hybridisation. None of the cases displayed a single positive tumour cell for all the viruses tested
whatever the technique applied. Of note, in five cases of tumours with lymphoid infiltrates, we detected scattered EBV (EBER)-
positive bystander lymphocytes. In three cases, a faint nuclear staining was found with the anti-latent nuclear antigen/LANA1 (HHV-
8) antibody. These cases were checked by PCR with two sets of primers (orf 26 and orf 75) and remained negative for this latter
virus. Taken together, our data strongly suggest that the conventional human oncogenic viruses (HPV, EBV, HCMV, HHV-8 and
SV40) are unlikely to play some role in the development of lung carcinomas.
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A few virus species have been detected in human cancers. In some
human tumours, these viruses probably play a critical role in
carcinogenesis since they are present early during the process of
cancer development and are constantly detectable in the tumour
cells. Among these, human T-cell leukaemia virus-1 (HTLV-1)
(Matsuoka, 2003), Epstein–Barr virus (EBV) (Macsween and
Crawford, 2003), human herpesvirus-8 (HHV-8) (Ganem, 1997)
and human papillomaviruses (HPV) (zur Hausen, 2000) are now
well recognised as oncogenic and are specifically associated with
different types of tumours. Other viruses have been incriminated
in human carcinogenesis but there is still a hard debate regarding
their direct implication in cancer, in particular concerning simian
virus 40 (SV40) (Carbone et al, 2003) and human cytomegalovirus
(HCMV) (Cobbs et al, 2002).
Large body of data have demonstrated the presence of SV40 in
different tumours in humans, but the majority of the studies have
relied on PCR detection of the viral genome (Bergsagel et al, 1992;
Galateau-Salle et al, 1998; Martini et al, 1996). There are still
controversies as to whether SV40 is directly linked to cancer
development. Early studies have shown that SV40 genome was
present in mesothelioma (Carbone et al, 1997), but immunodetec-
tion of SV40 as a diagnostic marker of human mesothelioma is not
carried out in routine pathology (Carbone et al, 2003).
Recent results have implicated HCMV in the pathogenesis of
malignant gliomas (Cobbs et al, 2002), prostate cancers (Samanta
et al, 2003) and colon cancers (Harkins et al, 2002; Samanta et al,
2003). The human cytomegalovirus is a b-herpesvirus able to infect
various types of human cells, including glial cells, endothelial cells
and epithelial cells (Hummel and Abecassis, 2002). As other
herpesviruses, HCMV infects 80% of the adult human population
and persists in reservoir cells throughout life. Nevertheless, this
virus is not yet recognised as an oncogenic factor, in particular in
vivo (Hsu et al, 2004).
The epidemiology of lung cancers remains partially unresolved
since the vast majority of tobacco users do not develop such
tumours while at least 10–15% of lung cancers occur in non
smokers (Alberg and Samet, 2003). Thus, factors other than
smoking may also have an impact as aetiological and risk factors
for lung cancer. Different studies have suggested that the HPVs
(Syrjanen, 2002), EBV (Grinstein et al, 2002) and to a less extent
SV40 (Galateau-Salle et al, 1998) may be involved in lung cancer
development, but the results are discrepant or underline some
geographical variations. A viral aetiology of lung tumours is
tantalising since the virus can be regarded as a main oncogenic
event (like HPV in genital tract) or as an important cofactor as in
human mesotheliomas (SV40 plus asbestosis).
In this study, we tried to address the question of a viral aetiology of
lung cancers by investigating a series of 122 cases of small cell lung
carcinomas (SCLC) and non-small cell lung carcinomas (NSCLC) with
immunohistochemistry and in situ hybridisation for the presence of
five different virus species (HPV, EBV, HHV-8, SV40, HCMV).
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Two tissue microarrays (TMAs) were used for this study. The array
blocks were constructed using a technique previously described
(Charafe-Jauffret et al, 2003) with a tissue arrayer from Beecher
Instruments (Beecher Instruments, Micro-array technology, Sun
Prairie, WI, USA). Cores (0.6mm) were taken from paraffin-
embedded SCLC and NSCLC retrieved from our files at the Purpan
Hospital in Toulouse between 1999 and 2002. Each tumour was
represented by two cores. A total of 40 tumour samples were
classified as squamous cell carcinoma (SCC), 31 as adenocarcino-
ma (AC), five as AC-SCC, four as large-cell lung cancer, nine as
small-cell lung cancer, 13 as large-cell neuroendocrine carcinoma,
seven as bronchioloalveolar carcinoma, three as atypical bronchial
carcinoid, six as typical bronchial carcinoid and four as
pleomorphic carcinoma.
The approval of the French equivalent of the Institutional
Review Board (Comite ´ Consultatif de Pre ´servation des Personnes
en Recherche Biologique/CCPPRB) was not required for such an
investigation based on archived paraffin blocks that have been
routinely used for diagnostic purposes.
Immunohistochemistry
Antibodies Anti-CMV: We used an anti-HCMV monoclonal anti-
body (clone E13, Argene-Biosoft, Varihes, France). It recognises
an immediate early antigen of HCMV (IE1) and does not cross
react with EBV, adenovirus, varicella-zoster virus and HSV. It
works very well in positive controls (working dilution 1:100) and
gives a strong nuclear staining in tissues (colitis) with active
HCMV infection. In addition, a weak cytoplasmic staining is seen
in virtually all infected cells. The staining of the positive controls
was obtained after standard antigen retrieval and/or after
amplification of the signal by catalysed system amplification
(CSA, Dako, Carpintera, CA, USA).
Anti-SV40: An anti-Tag antibody from Oncogene Research
Products (San Diego, CA, USA) was used. This antibody (Ab-2,
Clone Pab416) worked well on paraffin sections of tissues fixed
either in 10% buffered formalin or in Bouin’s liquid. The staining
of the positive control cell line was obtained after standard antigen
retrieval and/or after amplification of the signal by CSA. One
hepatocellular carcinoma cell line from T-Ag transgenic mice
(Weber-Benarous et al, 1993) and a case of renal infection (Li et al,
2002) were used as positive controls. For negative controls (DNA
negative), five tissue sections from T-Ag PCR-negative lung
tumours and non-neoplastic tissues were used.
Anti-HHV-8: The rat monoclonal anti-LANA-1 antibody (LN53)
(ABI, Columbia, MD, USA) was used at a dilution of 1:2000
according to a previously published protocol (Brousset et al,2 0 0 1 ) .
This antibody stains latently infected HHV-8-positive cells (Kaposi’s
sarcoma) and the signal is nuclear with a stippling pattern.
Anti-EBV: Two monoclonal antibodies (anti-EBNA2, clone PE2,
and anti-LMP1, clone CS1-4, Dako, Carpinteria, CA, USA) were
used as described in detail elsewhere (Brousset et al, 1994).
Lymphatic tissue from a patient with infectious mononucleosis
was used as positive control.
Anti-HPV: We used the anti-VP1 capsid protein (clone K1H8)
monoclonal antibody (Dako, Carpinteria, CA, USA). This antibody
recognises a nonconformational internal linear epitope of the
major capsid protein VP1. K1H8 antibody works well on paraffin
section and in thin layers of cervical smears, and detects various
types of viral strains (in particular, HPV type 6, 11, 16, 18, 31, 33,
42, 51, 52, 56 and 58) (Rouyer et al, 2004).
Immunohistochemical procedure Immunostaining on paraffin
sections was performed using the method described elsewhere
with little modifications (Brousset et al, 2001). Briefly, paraffin
sections were mounted on glass slides coated with silane (Sigma
Chemical Co, Saint Quentin, France). Sections were deparaffinized,
placed in 10mmolL
1 Na-citrate buffer (pH 6) and heated in a
microwave oven (Whirlpool model; Philips, Eindhoven, Holland)
at 900W for cycles of 20min and 10min. The slides were removed
from the oven and allowed to cool for 30min at room temperature.
After washing in water, endogenous peroxidase was blocked with
1% hydrogen peroxide in methanol for 30min. Slides were then
rinsed in PBS before staining with a streptavidin–biotin three-
stage technique, with the DAKO Strept ABC complex/HRP Duet kit
(Dako, code no. K492, Carpinteria, CA, USA). In parallel,
amplification with catalysed system amplification (CSA, Dako,
Carpinteria, CA, USA) was applied according to the supplier’s
recommendations. The Dako CSA system HRP is an extremely
sensitive immunohistochemical staining procedure incorporating
a signal amplification method based on the peroxidase catalyzed
deposition of a biotinylated compound followed by a secondary
reaction with streptavidin peroxidase (Dako, Carpinteria, CA,
USA).
In situ hybridisation
Human cytomegalovirus: This technique has been described
elsewhere (Brousset et al, 1992). A biotinylated DNA probe from
a commercial source (Enzo, PathoGene DNA probe assay, CMV
DNA probe pack, part no. 32802, Enzo Life Sciences Inc.,
Faimingdale, NY, USA) was used according to the manufacter’s
recommendations with some modifications. In our hands, there
was a clearcut correlation between in situ hybridisation and
immunohistochemistry for control tissues.
Epstein–Barr virus: We used the peptidic nucleic acid (PNA)
EBER1 probes from Dako (Carpinteria, CA, USA) according to the
manufacturer’s recommendations.
Human papillomavirus: Probes against strains 16-18-31-33-51
(from Enzo Life Sciences Inc., Faimingdale, NY, USA) were used
and applied with the same procedure as for HCMV.
PCR For PCR detection of HHV-8, amplification was performed
with standard protocols with DNA extracted from formalin-fixed
paraffin-embedded tissues. We chose the primer sets within orf 26
and orf 75 as previously described (Brousset et al, 2001). The other
viruses were not tested since they are ubiquitous and detectable as
bystanders in virtually all tissues tested.
RESULTS
Immunohistochemistry
All the antibodies against the specific proteins of the five viruses
tested in this study gave negative results in lung tumour tissues. All
controls tested in the same conditions stained reproducibly. Two
lymph nodes with infectious mononucleosis contained EBNA2
(PE2)- and LMP1 (CS1-4)-positive immunoblasts. Two lung
biopsies from patients with active HCMV replication contained
numerous IE1 (E13)-positive cells. Two cases of Kaposi’s sarcoma
and one case of multicentric Castleman’s disease were repeatedly
positive with anti-LNA1 antibody. Three cervical biopsies with
condyloma were used as positive controls for anti-HPV (K1H8)
antibody. Lastly, the two controls used to validate the anti-SV40
Tag antibody were positive in each experiment without using the
amplification (CSA) technique.
None of the cases of lung cancer included in this study
contained a single positive tumour cell with all the above-
referenced antibodies. In three cases of SCC, we found a faint
nuclear staining with the anti-LANA1 (HHV-8) antibody. This
signal was weak and diffuse and lacked the characteristic stippling
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spattern. Nevertheless, the absence of viral infection was confirmed
by PCR with two sets of primers (orf 26 and orf 75) (not shown).
In situ hybridisation
The results were very close to those of the immunohistochemistry
in that no tumour cell was detected with any of the probes. Of note,
in five cases with important lymphoid infiltrates (three AC, two
SCC), a few scattered small bystander lymphocytes were detected
with the EBER1 probes. We failed to detect a single positive case
with the several anti-HPV probes we used.
DISCUSSION
Besides some cases associated with HPV and rare cases infected by
EBV, the incidence of viral infection in lung carcinomas remains
marginal. We developed different techniques of detection of
viruses already incriminated in lung tumours (HPV and EBV) and
we extended our survey to viruses more recently implicated in
cancer (SV40, HCMV and HHV-8). We have been unable to detect
a single case (out of 122) positive for any of the five different
viruses tested.
To be suspected to play some role in human tumours, an
oncogenic virus should be specifically detected in the tumour cells.
This theory also implies that the virus is present in all cells of a
tumour in a monoclonal fashion, suggesting that the viral infection
is an early event consistent with a clonal expansion of the tumour
cells (Brousset et al, 1994) . In addition, a few viruses like EBV,
HCMV and sometimes HPV are ubiquitous and infect a high
percentage of people, rendering PCR investigations of the tumours
poorly reliable as PCR products can be yielded from bystander
infected cells. This is frequently the case with EBV (Meggetto et al,
1997) and also with HPV (Pett et al, 2004) and possibly SV40.
The detection rates of HPV in lung carcinomas are subject to
wide variations. In a recent review of 85 studies recording about
2500 cases, Syrjanen (2002) described a detection rate varying
from 0 to 100%. We failed to reproduce results obtained by other
groups who used the same techniques as ours, that is,
immunohistochemistry and in situ hybridisation. This discrepancy
may be explained at least in part by geographical epidemiological
variations since most studies with positive results for HPV were
performed in Asia (Miyagi et al, 2000; Cheng et al, 2001). However,
our results are also discrepant with those of the Finnish group of
Syrjanen et al (1989), who found a detection rate of 7% for HPV
among 131 patients with lung cancers. In order to clarify this
difference, it may be useful to look for the presence of HPV in lung
cancers of nonsmoking patients, where HPV could be found more
frequently as cocarcinogen. In our study, only four out of 122
patients were nonsmokers.
Epstein–Barr virus probably plays a sporadic role in lung
cancers (Grinstein et al, 2002). Only a few cases of EBV-associated
tumours have been reported in the literature. We failed to detect
EBV antigens in epithelial cells of our samples. EBV antigens were
investigated with the anti-EBNA2 and anti-LMP1 antibodies
because of a good sensibility and reproducibility of staining in
control slides with an adapted technique of antigen retrieval.
Moreover, the negativity of in situ hybridisation with EBER is the
strongest argument for the absence of the latently infected cells in
our tumours. Although our series is possibly biased since we had
only two cases with lymphoepithelial architecture, we can deduce
from our data that EBV is not at play in the most frequent types of
lung cancers.
Simian virus 40 genome and gene products have been detected
by some groups in mesotheliomas (Carbone et al, 2003). From
an epidemiological point of view, variation in positivity between
studies may be related to great geographical variation of
SV40 contamination of people through poliomyelitis vaccination.
Indeed, it is not possible to identify precisely individuals who
were exposed to SV40, as few vaccine batches were tested
for contamination, not all batches were contaminated and
distribution of contaminated batches from one country to another
was not controlled (Gazdar et al, 2002). Some authors
have suggested that the viral genes, in particular Tag, were weakly
expressed in mesotheliomas (Butel and Lednicky, 1999). However,
immunodetection of SV40 Tag is not commonly recognised as a
diagnostic marker enabling the distinction between mesothelioma
and adenocarcinoma, or between mesothelioma and reactive
mesothelial hyperplasia (Jasani, 1999). The lack of reproducibility
of immunohistochemistry is difficult to explain since there
are specific anti-Tag monoclonal antibodies that work well on
paraffin sections making it possible the detection of the virus
in physiological conditions. All of our cases have been tested in
parallel with a highly sensitive amplification method of
the immunohistochemical signal (CSA method), and a signal
was obtained with the positive controls only. Galateau-Salle et al
(1998) have reported the presence of SV40 DNA sequences
in mesotheliomas and also in lung cancers and in benign
(inflammatory) conditions as well. By immunohistochemistry,
we have investigated four cases of SV40-positive lung tumours
from this latter study and we obtained negative results in
all instances (data not shown). Last but not least, Lopez-Rios
et al recently published against a role for SV40 infection in
human mesothelioma. In more than 70 mesothelioma samples,
there lacked T-Ag-positive staining, such as in our experiments.
The authors also performed DNA extraction and PCR, and
found positive results only when primers were in the region
of T-Ag gene (nucleotides 4100–4713) that is present in
laboratory plasmids. Conversely, PCR were negative when
primers were not included within that region (Lopez-Rios
et al, 2004).
The negativity we found for HHV-8 is expected since so far this
virus has not been associated with epithelial tumours. Human
cytomegalovirus is not a good candidate in lung carcinogenesis as
well. Indeed, one group only has reported on the detection of this
virus in CNS tumours (Cobbs et al, 2002) and also in colonic
(Harkins et al, 2002) and prostate cancers (Samanta et al, 2003). As
far as the CNS tumours are concerned, we have been unable to
reproduce the results of the study by Cobbs et al. We have found
that the virus could be detected in only a few cases of CNS tumours
not in malignant cells but rather in putative stromal cells (Sabatier
et al, 2005; data not shown).
The major conclusion of our study is that the main oncogenic
viruses usually found in solid tumours in humans are not
implicated in the vast majority of lung carcinomas.
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